Migraine

18 trials 9 recruiting MedDRA PT
18 Registered trials
9 Recruiting
7 Unique sponsors
5 Unique IMPs
15 Commercial trials
Drug classes (ATC)
— ATC code not specified 9
N Neurology/Psychiatry (ATC N) 9
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Monoclonal antibody 1 substance
Monoclonal antibody (neural, humanized) 1 substance
Phase III: 10 Phase II: 1 Phase IV: 5 Phase I (Other): 1 Other: 1

Filter these 18 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 18 trials

Phase III

10 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ATOGEPANT
    2022-501099-24-00 11 countries 2023 n=127
    Recruiting
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ATOGEPANT
    2023-506029-12-00 10 countries 2024 n=1,013
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ATOGEPANT
    2023-507096-21-00 9 countries 2021 n=382
    Ended
  • Amgen Inc. Commercial
    ERENUMAB
    2023-504928-26-00 5 countries 2019 n=101
    Ended
  • Amgen Inc. Commercial
    ERENUMAB
    2023-504930-23-00 7 countries 2019 n=233
    Ended
  • H. Lundbeck A/S Commercial
    EPTINEZUMAB
    2022-502917-27-00 4 countries 2023 n=276
    Recruiting
  • H. Lundbeck A/S Commercial
    EPTINEZUMAB
    2024-510656-13-00 4 countries 2022 n=174
    Recruiting
  • Pfizer Inc. Commercial
    RIMEGEPANT
    2024-512382-13-00 4 countries 2022 n=415
    Recruiting
  • Pfizer Inc. Commercial
    RIMEGEPANT
    2024-512743-23-00 3 countries 2021 n=155
    Recruiting
  • Pfizer Inc. Commercial
    RIMEGEPANT
    2024-512744-32-00 2 countries 2022 n=98
    Recruiting

Phase II

1 trial
  • H. Lundbeck A/S Commercial
    LU AG09222
    2023-508821-28-00 11 countries 2024 n=552
    Ended

Phase IV

5 trials
  • H. Lundbeck A/S Commercial
    EPTINEZUMAB
    2024-510729-24-00 8 countries 2022 n=720
    Ended
  • Pfizer Inc. Commercial
    RIMEGEPANT
    2024-513269-37-00 10 countries 2023 n=397
    Ended
  • Pfizer Inc. Commercial
    RIMEGEPANT
    2024-513270-21-00 9 countries 2023 n=470
    Ended
  • Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca Academic
    IMP not specified
    2024-519770-38-00 1 country 2026 n=24
    Recruiting
  • Ospedale San Raffaele S.r.l. Academic
    EPTINEZUMAB
    2024-519337-35-00 1 country 2026 n=60
    Recruiting

Phase I (Other)

1 trial
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Academic
    IMP not specified
    2023-504690-21-00 1 country n=30
    Pending

Other

1 trial
  • Pfizer Inc. Commercial
    IMP not specified
    2025-525125-12-00 1 country 2026 n=36
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 6 Other, Phase III, Phase IV 4
H. Lundbeck A/S Commercial 4 Phase II, Phase III, Phase IV 2
AbbVie Deutschland GmbH & Co. KG Commercial 3 Phase III 1
Amgen Inc. Commercial 2 Phase III 0
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Academic 1 Phase I (Other) 0
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca Academic 1 Phase IV 1
Ospedale San Raffaele S.r.l. Academic 1 Phase IV 1
New trials by year
2019
2
2021
2
2022
4
2023
4
2024
2
2026
3
← All indication landscapes